



事 務 連 絡  
平成17年3月28日

各都道府県衛生主管部（局）薬務主管課 御中

厚生労働省医薬食品局安全対策課

「承認後の安全性情報の取扱い：緊急報告のための用語の定義と報告の基準」  
（ICH E2D ガイドライン）に関する Q&A について

「承認後の安全性情報の取扱い：緊急報告のための用語の定義と報告の基準」  
（ICH E2D ガイドライン）については、平成17年3月28日付薬食安発第  
0328007 号厚生労働省医薬食品局安全対策課長通知により通知したところ  
であるが、今般、これに関連して、別添のとおり Q&A を作成したので、御了知  
の上、貴管下関係業者に対し周知徹底方御配慮願いたい。

なお、本事務連絡の適用に伴い、平成15年8月21日付事務連絡「副作用  
等報告に関する Q&A について」の別紙2の A22 を、本事務連絡別添の A6  
に改める。

(別添)

## 「承認後の安全性情報の取扱い：緊急報告のための用語の定義と報告の基準」(ICH E2D ガイドライン) に関する Q&A

### ○「2.2 副作用」について

Q1：「「医薬品に対する反応」とは、医薬品と有害事象との間に、少なくとも合理的な因果関係の可能性のあるものをいう (ICH E2A ガイドラインを参照のこと)」とはどういうことか？

A1：ICH E2A ガイドラインに「医薬品に対する反応とは、有害事象のうち当該医薬品との因果関係が否定できないものをいう」とあるように、当該医薬品と有害事象との因果関係が否定できるもの以外のものを「医薬品に対する反応」と考えるべきであり、因果関係が不明なものも含まれる。

なお、ICH E2A ガイドラインでは、因果関係の考え方に関して、その評価の重要性も含め述べられているので参照されたい。

### ○「2.3 重篤な有害事象又は副作用」について

Q2：「(3)治療のための入院又は入院期間の延長が必要であるもの」とあるが、ガイドラインの原文は、“requires inpatient hospitalisation ...”であり、「治療のための入院」という内容は記載されていない。どのように考えたらよいか？

A2：従来のお取扱いと同様に、副作用治療のために入院又は入院期間の延長が必要となった事例について報告を求めるという趣旨に鑑み、翻訳に当たってその旨を明確にした。したがって、「治療のための入院」には、検査を行うための入院及び副作用が治癒又は軽快しているものの経過観察をするための入院は含まれない (平成15年8月21日付 厚生労働省医薬食品局安全対策課・審査管理課事務連絡「副作用等報告に関するQ&Aについて」のQ&A 33を参照のこと)。

### ○「2.4 予測できない副作用」について

Q3：「添付文書に記載されている副作用でも、致命的な転帰となるおそれがあることが明記されていない限り、致命的な転帰を伴う当該副作用は予測できない副作用と判断すべきである」とあるが、医療用医薬品の場合、添付文書のどの欄にどのような記載がある場合に予測できる副作用と判断できるのか？

A3：「警告」、「重要な基本的注意」、「重大な副作用」等の項において、当該副

作用により致命的な転帰をたどることがある旨が明記されている場合は、予測できる副作用と判断してよい。

○「3.1.1 自発報告」について

Q 4 : 「一般使用者からの報告は、「医学的な裏付け」の有無とは関係なく、自発報告として取り扱うべきである」とあるが、具体的にどのような対応が求められるのか？

A 4 : 一般使用者からの情報しか得られない場合であっても、医師等からの情報も得られている場合（＝「医学的な裏付け」がある場合）と同様に、自発報告として適切に評価するとともに、薬事法施行規則第253条第1項各号に該当する場合には、定められた報告期限内に報告すること。

○「3.1.2 文献」について

Q 5 : 共同開発品等の場合には、各々の製造販売業者から独立行政法人医薬品医療機器総合機構（以下「機構」という。）に個別症例安全性報告を行うのか？

A 5 : そのとおりである。なお、各々の製造販売業者が機構への個別症例安全性報告の責任を有する。

Q 6 : 「当該医薬品の製造販売業者、商標又は商品名が特定されない場合、明確になるまでは自社の製品と想定すべきである」とあるが、製造販売業者が商品名を特定できないような副作用等情報を入手した場合は、当該情報を入手した時点から報告期限が起算されると解釈すべきか？

A 6 : 商品名等が特定できない場合であっても、自社の製品として取り扱い、当該情報入手日を起算日として、薬事法施行規則第253条第1項に定める報告期限内に個別症例安全性報告を行うこと。

なお、追加情報により他社の製品と判明した場合には、当該個別症例安全性報告について取り下げ報告を行うこと。

○「3.1.3 インターネット」について

Q 7 : 「インターネットから知った自発的な報告は、自発報告として取り扱うべきである」とあるが、「2.2 副作用」の項の「たとえ因果関係について不明又は明確に述べられていなくても、規制当局への報告目的からすれば、副作用の定義を満たすことになる」との記述からすると、インターネット上で知り得た報告はすべて副作用として取り扱うべきか？

A 7 : インターネットから知った自発報告についても、それ以外の手段で得られた自発報告と同様に扱うこと。その際、Q&A 8にもあるように、

報告者の特定に留意する必要がある。

なお、自発報告については、副作用報告の目的からして、因果関係が疑われていることを示唆しているものとみなされる点に留意されたい。

Q 8 : 「インターネット、例えば電子メールから得られた症例に関して、報告者の特定とは実際に人が存在すること、すなわち、患者と報告者の存在を確認することが可能であるということの意味する」とあるが、報告者が実際に存在することの確認は、電子メールのアドレスやインターネットの URL が判明しているだけでも可能と考えるべきか、又は報告者の名前（イニシャル）等が判明している場合に可能と考えるべきか？

A 8 : 電子メールのアドレスやインターネットの URL が判明している場合は、それを利用することにより報告者に対する確認が可能という意味で、報告者が実在していると考えべきである。

○ 「3.2 依頼に基づく非自発的な情報源 (Solicited Sources)」について

Q 9 : 日本の「使用成績調査」、「特定使用成績調査」及び「市販直後調査」は、「依頼に基づく非自発的な情報源」に該当するか？

A 9 : 「使用成績調査」及び「特定使用成績調査」は、「依頼に基づく非自発的な情報源」に該当する。

一方、「市販直後調査」は、医療機関に対し、新医薬品の適正使用に関する理解を繰り返し促すとともに、重篤な副作用等が発生した場合の速やかな報告を依頼するものであり、通常、特定の症例や特定の副作用を対象として系統的に副作用情報の収集を行うものではないため、「自発的な情報源」に該当する。

○ 「3.3 企業間の契約に基づく情報」について

Q 10 : 「契約上の取決めがどうであろうとも、製造販売業者が最終的に規制当局への報告の責任を負う」とはどういう意味か？

A 10 : 同一製品を販売提携等により複数の企業が取り扱う場合であっても、副作用等の報告については、当該医薬品の製造販売業者（又は外国特例承認取得者）に責務があるという意味である。

なお、この場合、製造販売業者又は販売提携等に関わる企業のうち、いずれかが最初に報告対象となる情報を入手した日が報告起算日となる。

○「4.1.1 重篤な副作用」について

Q 1 1 : 「臨床試験その他の依頼に基づく非自発的な情報源から得られる報告の場合は、報告者である医療専門家又は製造販売業者により、当該医薬品との因果関係の可能性があると評価された症例はすべて副作用とみなされる」とあるが、因果関係が不明な場合は副作用と考えなくてよいのか？

A 1 1 : 因果関係が不明な場合も因果関係が否定できないので、副作用として取り扱うべきである。

○「4.1.2.1 有効性の欠如」について

Q 1 2 : 「特定の地域における特定の状況下では、有効性の欠如に関する個別症例報告が緊急報告の対象とみなされる場合もある。これらの例としては、致命的又は重篤な疾患の治療に使用される医薬品、ワクチン及び避妊薬がある」とあるが、日本ではどのように取り扱うのか？

A 1 2 : 個々の症例における有効性の欠如の情報は、承認時等に特に求められた場合を除き、通常、個別症例安全性報告を行う必要はないが、疫学調査等ある一定の集団で見た場合にそのような知見が得られた際には、研究報告として報告すること。

○「4.3 起算日」について

Q 1 3 : 「以前に報告した症例について、追加の医学的に重要な情報を入手した場合、追加報告の提出には、規制上の報告期限が再度起算される」とあるが、具体的にどのような場合が該当するか？

A 1 3 : 例えば、以前に報告した副作用とは別の重篤な副作用に関する情報を追加で入手した場合、初回報告時に「不明」であった転帰が「死亡」、「回復したが後遺症あり」又は「未回復」であることが判明した場合、当該医薬品の再投与後の臨床経過等を入手した場合、その他医薬品との因果関係を含め、症例の臨床的評価に重大な影響を及ぼす可能性のある情報を入手した場合等が該当する。

なお、既知・重篤の副作用症例として30日以内に報告した症例について、未知・重篤の副作用の追加等、本来は15日以内の報告対象となる情報を追加で入手した場合には、当該追加情報を入手後15日以内に追加報告を行うこと。

○「4.4 重篤でない副作用」について

Q14：「重篤でない副作用については、ICH E2C ガイドラインに従って定期的安全性最新報告において報告すべきである」とあるが、「依頼に基づく非自発的な情報源」から得られた「重篤でない副作用」はどのように取り扱えばよいか？

A14：「依頼に基づく非自発的な情報源」から得られた「重篤でない副作用」は、定期的安全性最新報告（PSUR）におけるラインリストに記載する症例の対象とはされていないが、製造販売業者として、安全対策の面から集積及び検討が必要である。また、国内の未知・非重篤の副作用については、薬事法施行規則第253条第1項第3号の規定に基づき、定期報告を行う必要がある点にも留意されたい。

○「5.4.1 妊娠中の曝露」について

Q15：「製造販売業者は、自社の医薬品に胚／胎児が曝露されていた可能性がある場合、医療専門家又は一般使用者から得られた、そのような妊娠に関するすべての報告を追跡調査することが期待される」とあるが、どのように対応すべきか？

A15：可能な限り、生まれた児に対する当該医薬品の影響の有無が確認できるよう、各社において、具体的な手順を定めておくこと。

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL  
REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN  
USE

**ICH HARMONISED TRIPARTITE GUIDELINE**

**POST-APPROVAL SAFETY DATA MANAGEMENT:  
DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING  
E2D**

Recommended for Adoption  
at Step 4 of the ICH Process  
on 12 November 2003  
by the ICH Steering Committee

*This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA*

**POST-APPROVAL SAFETY DATA MANAGEMENT:  
DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING**

**ICH Harmonised Tripartite Guideline**

Having reached *Step 4* of the ICH Process at the ICH Steering Committee meeting on 12 November 2003, this guideline is recommended for adoption to the three regulatory parties to ICH

**TABLE OF CONTENTS**

<b>1.</b>	<b>INTRODUCTION.....</b>	<b>1</b>
<b>2.</b>	<b>DEFINITIONS AND TERMINOLOGY ASSOCIATED WITH POST-APPROVAL DRUG SAFETY EXPERIENCE.....</b>	<b>1</b>
2.1	Adverse Event (AE).....	1
2.2	Adverse Drug Reaction (ADR).....	1
2.3	Serious AE/ADR.....	1
2.4	Unexpected ADR.....	2
2.5	Healthcare Professional.....	2
2.6	Consumer.....	2
<b>3.</b>	<b>SOURCES OF INDIVIDUAL CASE SAFETY REPORTS .....</b>	<b>3</b>
3.1	Unsolicited Sources .....	3
3.1.1	Spontaneous Reports.....	3
3.1.2	Literature .....	3
3.1.3	Internet .....	3
3.1.4	Other Sources.....	4
3.2	Solicited Sources .....	4
3.3	Contractual Agreements .....	4
3.4	Regulatory Authority Sources .....	4
<b>4.</b>	<b>STANDARDS FOR EXPEDITED REPORTING .....</b>	<b>5</b>
4.1	What Should Be Reported?.....	5
4.1.1	Serious ADRs .....	5
4.1.2	Other Observations .....	5
4.1.2.1	<i>Lack of Efficacy</i> .....	5



4.1.2.2	Overdose.....	5
4.2	Minimum Criteria for Reporting.....	5
4.3	Reporting Time Frames.....	6
4.4	Non-serious ADRs.....	6
5.	<b>GOOD CASE MANAGEMENT PRACTICES</b> .....	<b>6</b>
5.1	Assessing Patient and Reporter Identifiability <sup>1</sup> .....	6
5.2	The Role of Narratives.....	7
5.3	Clinical Case Evaluation.....	7
5.4	Follow-up Information.....	7
5.4.1	Pregnancy Exposure.....	8
5.5	How to Report.....	8
	<b>REFERENCES</b> .....	<b>9</b>
	<b>ATTACHMENT</b> .....	<b>10</b>

# **POST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING**

## **1. INTRODUCTION**

It is important to establish an internationally standardized procedure in order to improve the quality of post-approval safety information and to harmonise the way of gathering and reporting information. The ICH E2A guideline provides guidance on pre-approval safety data management. Although many stakeholders have applied ICH E2A concepts to the post-approval phase, there is a need to provide further guidance on definitions and standards for post-approval expedited reporting, as well as good case management practices. This guideline is based on the content of ICH E2A guideline, with consideration as to how the terms and definitions can be applied in the post-approval phase of the product life cycle.

## **2. DEFINITIONS AND TERMINOLOGY ASSOCIATED WITH POST-APPROVAL DRUG SAFETY EXPERIENCE**

### **2.1 Adverse Event (AE)**

An adverse event is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (for example, an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.

### **2.2 Adverse Drug Reaction (ADR)**

Adverse drug reactions, as established by regional regulations, guidance, and practices, concern noxious and unintended responses to a medicinal product.

The phrase "responses to a medicinal product" means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility (refer to the ICH E2A guideline).

A reaction, in contrast to an event, is characterized by the fact that a causal relationship between the drug and the occurrence is suspected. For regulatory reporting purposes, if an event is spontaneously reported, even if the relationship is unknown or unstated, it meets the definition of an adverse drug reaction.

### **2.3 Serious AE/ADR**

In accordance with the ICH E2A guideline, a serious adverse event or reaction is any untoward medical occurrence that at any dose:

- \* results in death,
- \* is life-threatening  
(NOTE: The term "life-threatening" in the definition of "serious" refers to an event/reaction in which the patient was at risk of death at the time of the event/reaction; it does not refer to an event/ reaction which hypothetically might have caused death if it were more severe),
- \* requires inpatient hospitalisation or results in prolongation of existing hospitalisation,
- \* results in persistent or significant disability/incapacity,

- \* is a congenital anomaly/birth defect,
- \* is a medically important event or reaction.

Medical and scientific judgment should be exercised in deciding whether other situations should be considered serious such as important medical events that might not be immediately life-threatening or result in death or hospitalisation but might jeopardise the patient or might require intervention to prevent one of the other outcomes listed in the definition above. Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.

#### **2.4 Unexpected ADR**

An ADR whose nature, severity, specificity, or outcome is not consistent with the term or description used in the local/regional product labeling (e.g. Package Insert or Summary of Product Characteristics) should be considered unexpected. When a Marketing Authorisation Holder (MAH) is uncertain whether an ADR is expected or unexpected, the ADR should be treated as unexpected.

An expected ADR with a fatal outcome should be considered unexpected unless the local/regional product labeling specifically states that the ADR might be associated with a fatal outcome.

“Class ADRs” should not automatically be considered to be expected for the subject drug. “Class ADRs” should be considered expected only if described as specifically occurring with the product in the local/regional product labeling. This is illustrated in the following examples:

- “As with other drugs of this class, the following undesirable effect occurs with Drug X.”
- “Drugs of this class, including Drug X, can cause...”

If the ADR has not been documented with Drug X, statements such as the following are likely to appear in the local/regional product labeling:

- “Other drugs of this class are reported to cause...”
- “Drugs of this class are reported to cause..., but no reports have been received to date with Drug X.”

In these situations, the ADR should not be considered as expected for Drug X.

NOTE: The term “listedness” is not applicable to expedited reporting but should be used to characterize the ADR according to the Company Core Safety Information (refer to ICH E2C guideline for definitions).

#### **2.5 Healthcare Professional**

Healthcare professional is defined as a medically-qualified person such as a physician, dentist, pharmacist, nurse, coroner, or as otherwise specified by local regulations.

#### **2.6 Consumer**

Consumer is defined as a person who is not a healthcare professional such as a patient, lawyer, friend, or relative of a patient.

### **3. SOURCES OF INDIVIDUAL CASE SAFETY REPORTS**

#### **3.1 Unsolicited Sources**

##### **3.1.1 Spontaneous Reports**

A spontaneous report is an unsolicited communication by a healthcare professional or consumer to a company, regulatory authority or other organization (e.g. WHO, Regional Center, Poison Control Center) that describes one or more adverse drug reactions in a patient who was given one or more medicinal products and that does not derive from a study or any organized data collection scheme.

Stimulated reporting can occur in certain situations, such as notification by a "Dear Healthcare Professional" letter, publication in the press, or questioning of healthcare professionals by company representatives. These reports should be considered spontaneous.

Consumer adverse reaction reports should be handled as spontaneous reports irrespective of any subsequent "medical confirmation". Regulatory Authorities might require medical confirmation for the purpose of expedited reporting. Emphasis should be placed on the quality of the report and not on its source. Even if reports received from consumers do not qualify for regulatory reporting, the cases should be retained.

##### **3.1.2 Literature**

Each MAH is expected to regularly screen the worldwide scientific literature by accessing widely used systematic literature reviews or reference databases. The frequency of the literature searches should be according to local requirements or at least every two weeks. Cases of ADRs from the scientific and medical literature, including relevant published abstracts from meetings and draft manuscripts, might qualify for expedited reporting. A regulatory reporting form with relevant medical information should be provided for each identifiable patient. The publication reference(s) should be given as the report source; additionally a copy of the article might be requested by the local regulatory authority to accompany the report. All company offices are encouraged to be aware of publications in their local journals and to bring them to the attention of the company safety department as appropriate.

The regulatory reporting time clock starts as soon as the MAH has knowledge that the case meets minimum criteria for reportability.

If the product source, brand, or trade name is not specified, the MAH should assume that it was its product, although the report should indicate that the specific brand was not identified.

If multiple products are mentioned in the article, a report should be submitted only by the applicant whose product is suspected. The suspect product is that identified as such by the article's author.

##### **3.1.3 Internet**

MAHs should regularly screen websites under their management or responsibility for potential ADR case reports. MAHs are not expected to screen external websites for ADR information. However, if an MAH becomes aware of an adverse reaction on a website that it does not manage, the MAH should review the case and determine whether it should be reported.

MAHs should consider utilising their websites to facilitate ADR data collection, e.g., by providing ADR forms for reporting or by providing appropriate contact details for direct communication.

Unsolicited cases from the Internet should be handled as spontaneous reports. For the determination of reportability, the same criteria should be applied as for cases provided via other ways.

In relation to such cases from the Internet e.g. e-mail, identifiability of the reporter refers to the existence of a real person, i.e., it is possible to verify that the patient and the reporter exist.

### **3.1.4 Other Sources**

If an MAH becomes aware of a case report from non-medical sources, e.g. the lay press or other media, it should be handled as a spontaneous report. For the determination of reportability, the same criteria should be applied as for other reports.

## **3.2 Solicited Sources**

Solicited reports are those derived from organized data collection systems, which include clinical trials, registries, post-approval named patient use programs, other patient support and disease management programs, surveys of patients or healthcare providers, or information gathering on efficacy or patient compliance. Adverse event reports obtained from any of these should not be considered spontaneous.

For the purposes of safety reporting, solicited reports should be classified as study reports, and therefore should have an appropriate causality assessment by a healthcare professional or an MAH. Further guidance on study-related issues, such as managing blinded therapy cases, can be found in the ICH E2A guideline.

## **3.3 Contractual Agreements**

The marketing of many medicines increasingly takes place through contractual agreements between two or more companies, which may market same product in the same or different countries/region. Arrangements vary considerably with respect to inter-company communication and regulatory responsibilities. Overall, this can be a complex issue.

In such relationships, it is very important that explicit licensing/contractual agreements specify the processes for exchange of safety information, including timelines and regulatory reporting responsibilities. Safety personnel should be involved in development of any agreements from the beginning. Processes should be in place to avoid duplicate reporting to the regulatory authority, e.g. assigning responsibility to one company for literature screening.

Whatever the nature of the arrangement, the MAH is ultimately responsible for regulatory reporting. Therefore, every reasonable effort should be made between the contracting partners to minimize the data exchange period so as to promote compliance with MAH responsibilities.

## **3.4 Regulatory Authority Sources**

Individual serious unexpected adverse drug reaction reports originating from foreign regulatory authorities are subject to expedited reporting to other authorities by each MAH. Re-submission of serious ADR cases without new information to the

originating regulatory authority is not usually necessary, unless otherwise specified by local regulation.

## **4. STANDARDS FOR EXPEDITED REPORTING**

### **4.1 What Should Be Reported?**

#### **4.1.1 Serious ADRs**

Cases of adverse drug reactions that are both serious and unexpected are subject to expedited reporting. The reporting of serious expected reactions in an expedited manner varies among countries. Non-serious adverse reactions, whether expected or not, would normally not be subject to expedited reporting.

For reports from studies and other solicited sources, all cases judged by either the reporting healthcare professional or the MAH as having a possible causal relationship to the medicinal product would qualify as ADRs. For purposes of reporting, spontaneous reports associated with approved drugs imply a suspected causal relationship.

#### **4.1.2 Other Observations**

In addition to single case reports, any safety information from other observations that could change the risk-benefit evaluation for the product should be communicated as soon as possible to the regulatory authorities in accordance with local regulation. Examples include any significant unanticipated safety findings from an *in vitro*, animal, epidemiological, or clinical study that suggest a significant human risk, such as evidence of mutagenicity, teratogenicity, carcinogenicity, or lack of efficacy with a drug used in treating a life-threatening or serious disease.

##### **4.1.2.1 Lack of Efficacy**

Evidence of lack of efficacy should not normally be expedited, but should be discussed in the relevant periodic safety update report. However, in certain circumstances and in some regions, individual reports of lack of efficacy are considered subject to expedited reporting. Medicinal products used for the treatment of life-threatening or serious diseases, vaccines, and contraceptives are examples of classes of medicinal products where lack of efficacy should be considered for expedited reporting. Clinical judgment should be used in reporting, with consideration of the local product labeling and disease being treated.

##### **4.1.2.2 Overdose**

Reports of overdose with no associated adverse outcome should not be reported as adverse reactions. Cases associated with serious adverse reactions are considered subject to expedited reporting, unless otherwise specified by local regulation. They should be routinely followed up to ensure that the information is as complete as possible with regard to symptoms, treatment, and outcome. The MAH should collect any available information on overdose related to its products.

### **4.2 Minimum Criteria for Reporting**

It is recommended that as much information as possible be collected at the time of the initial report. However, for the purpose of regulatory reporting, the minimum data elements for an ADR case are: an identifiable reporter, an identifiable patient, an adverse reaction, and a suspect product. Lack of any of these four elements means

that the case is considered incomplete; however, MAHs are expected to exercise due diligence to collect the missing data elements.

### **4.3 Reporting Time Frames**

In general, expedited reporting of serious and unexpected ADRs is required as soon as possible, but in no case later than 15 calendar days of initial receipt of the information by the MAH. Time frames for other types of serious reports vary among countries, depending on source, expectedness and outcome.

The regulatory reporting time clock is considered to start on the date when any personnel of the MAH first receive a case report that fulfills minimum criteria as well as the criteria for expedited reporting. In general, this date should be considered day 0.

When additional medically relevant information is received for a previously reported case, the reporting time clock is considered to begin again for submission of the follow-up report. In addition, a case initially classified as a non-expedited report, would qualify for expedited reporting upon receipt of follow-up information that indicates the case should be re-classified (e.g., from non serious to serious).

### **4.4 Non-serious ADRs**

Cases of non-serious ADRs, whether expected or not, would not normally be considered reportable on an expedited basis. Non-serious ADRs should be included in the periodic safety update report according to the ICH E2C guideline.

## **5. GOOD CASE MANAGEMENT PRACTICES**

Accurate, complete, and bona fide information is very important for MAHs and regulatory agencies identifying and assessing ADR reports. Both are faced with the task of acquiring sufficient information to help ensure that the reports are authentic, accurate, as complete as possible, and non-duplicative.

### **5.1 Assessing Patient and Reporter Identifiability<sup>1</sup>**

Patient and reporter identifiability is important to avoid case duplication, detect fraud, and facilitate follow-up of appropriate cases. The term identifiable in this context refers to the verification of the existence of a patient and a reporter.

Local data privacy laws regarding patient and reporter identifiability might apply.

One or more of the following should automatically qualify a patient as identifiable: age (or age category, e.g., adolescent, adult, elderly), gender, initials, date of birth, name, or patient identification number. In addition, in the event of second-hand reports, every reasonable effort should be made to verify the existence of an identifiable patient and reporter.

All parties supplying case information or approached for case information should be identifiable: not only the initial reporter (the initial contact for the case), but also others supplying information.

In the absence of qualifying descriptors, a report referring to a definite number of patients should not be regarded as a case until the minimum four criteria for case reporting are met. For example, "Two patients experienced..." or "a few patients experienced" should be followed up for patient-identifiable information before regulatory reporting.

## **5.2 The Role of Narratives**

The objective of the narrative is to summarize all relevant clinical and related information, including patient characteristics, therapy details, medical history, clinical course of the event(s), diagnosis, and ADR(s) including the outcome, laboratory evidence (including normal ranges), and any other information that supports or refutes an ADR. The narrative should serve as a comprehensive, stand-alone "medical story". The information should be presented in a logical time sequence; ideally this should be presented in the chronology of the patient's experience, rather than in the chronology in which the information was received. In follow-up reports, new information should be clearly identified.

Abbreviations and acronyms should be avoided, with the possible exception of laboratory parameters and units. Key information from supplementary records should be included in the report, and their availability should be mentioned in the narrative and supplied on request. Any relevant autopsy or post-mortem findings should also be summarized in the narrative and related documents should be provided according to local regulation and if allowed by local data privacy laws.

Terms (e.g., AEs/ADRs, indication, and medical conditions) in the narrative should be accurately reflected in appropriate data fields.

## **5.3 Clinical Case Evaluation**

The purpose of careful medical review is to ensure correct interpretation of medical information. Preferably, information about the case should be collected from the healthcare professionals who are directly involved in the patient's care. Regardless of the source of an ADR report, the recipient should carefully review the report for the quality and completeness of the medical information. The review should include, but is not limited to, the following considerations:

- Is a diagnosis possible?
- Have the relevant diagnostic procedures been performed?
- Were alternative causes of the reaction(s) considered?
- What additional information is needed?

ADR terms should be used consistently and in accordance with recommended standards for diagnosis, if possible. The report should include the verbatim term as used by the reporter, or an accurate translation of it. Any company personnel receiving reports should provide an unbiased and unfiltered report of the information from the reporter. While the report recipient is encouraged to actively query the reporter to elicit the most complete account possible, inferences and imputations should be avoided in report submission. However, clearly identified evaluations by the MAH are considered appropriate and are required by some regulatory authorities.

When a case is reported by a consumer, his/her description of the event should be retained, although confirmatory or additional information from any relevant healthcare professionals should also be sought and included.

## **5.4 Follow-up Information**

The information from ADR cases when first received is generally incomplete. Ideally, comprehensive information would be available on all cases, but in practice efforts



should be made to seek additional information on selected reports, including second – hand reports (see Attachment, Recommended Key Data Elements, of this guideline).

In any scheme to optimize the value of follow-up, the first consideration should be prioritization of case reports by importance. The priority for follow-up should be as follows: cases which are 1) serious and unexpected, 2) serious and expected, and 3) non-serious and unexpected. In addition to seriousness and expectedness as criteria, cases “of special interest” also deserve extra attention as a high priority (e.g., ADRs under active surveillance at the request of the regulators), as well as any cases that might lead to a labeling change decision.

Follow-up information should be obtained, via a telephone call and/or site visit and/or a written request. The company should provide specific questions it would like to have answered. Follow-up methods should be tailored towards optimizing the collection of missing information. Written confirmation of details given verbally should be obtained whenever possible. In exceptional circumstances, if requests for information have been refused by the reporter, a regulatory authority might be able to assist an MAH in obtaining follow-up data.

To facilitate the capture of clinically relevant and complete information, use of a targeted questionnaire/specific form is encouraged, preferably at the time of the initial report. Ideally, healthcare professionals with thorough pharmacovigilance training and therapeutic expertise should be involved in the collection and the direct follow-up of reported cases (particularly those of medical significance). For serious ADRs, it is important to continue follow-up and report new information until the outcome has been established or the condition is stabilized. How long to follow up such cases is a matter of judgment.

It is important that at the time of the original report, sufficient details about the patient and reporter be collected and retained to enable future investigations, within the constraints imposed by local data privacy laws.

#### **5.4.1 Pregnancy Exposure**

MAHs are expected to follow up all pregnancy reports from healthcare professionals or consumers where the embryo/foetus could have been exposed to one of its medicinal products. When an active substance, or one of its metabolites, has a long half-life, this should be taken into account when considering whether a foetus could have been exposed (e.g., if medicinal products taken before the gestational period should be considered).

#### **5.5 How to Report**

The CIOMS I form has been a widely accepted standard for expedited adverse event reporting. However, no matter what the form or format used, it is important that certain basic information/data elements, when available, be included with any expedited report, whether in a tabular or narrative presentation. It is recommended that the Medical Dictionary for Regulatory Activities (MedDRA) be used for coding medical information. The standards for electronic submission of Individual Case Safety Reports (ICSRs), according to the ICH E2B/M2 guidelines, should be implemented.

The listing in the Attachment of this guideline addresses those data elements regarded as desirable; if all relevant elements are not available at the time of expedited reporting, efforts should be made to obtain them.

## **REFERENCES**

1. Current Challenges in Pharmacovigilance: Pragmatic Approaches (Report of CIOMS Working V), Geneva 2001
2. Rules Governing Medicinal Products in the European Union, Volume 9, PHARMACOVIGILANCE: Medicinal Products for Human Use, 2001 <http://pharmacos.eudra.org/F2/eudralex/vol-9/home.htm>
3. Guidance for Industry: Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines, Food and Drug Administration, March 2001 (draft) <http://www.fda.gov/cder/guidance/4153dft.pdf>
4. Safety Reporting Requirements for Human, Drug and Biological Products, Proposed Rule, Food and Drug Administration, March 2003
5. Notification No 421 on Enforcement of the Law Revising Partially the Pharmaceutical Affairs Law, the Director General, Pharmaceutical Affairs Bureau, Ministry of Health and Welfare, March 1997

## **ATTACHMENT**

### **RECOMMENDED KEY DATA ELEMENTS FOR INCLUSION IN EXPEDITED REPORTS OF SERIOUS ADVERSE DRUG REACTIONS**

Some data elements might not be relevant, depending on the circumstances. Attempts should be made to obtain follow-up information on as many other listed items as are pertinent to the case. Refer to the ICH E2B/M2 guidelines for detailed data elements for electronic transmission of ICSRs.

#### **1. Patient Details**

- Initials
- Other relevant identifier (patient number, for example)
- Gender
- Age, age category (e.g., adolescent, adult, elderly), or date of birth
- Concomitant conditions
- Medical history
- Relevant family history

#### **2. Suspected Medicinal Product(s)**

- Brand name as reported
- International Non-Proprietary Name (INN)
- Batch/lot number
- Indication(s) for which suspect medicinal product was prescribed or tested
- Dosage form and strength
- Daily dose (specify units - e.g., mg, ml, mg/kg) and regimen
- Route of administration
- Starting date and time
- Stopping date and time, or duration of treatment

#### **3. Other Treatment(s)**

The same information as in item 2 should be provided for the following:

- Concomitant medicinal products  
(including non-prescription, over-the-counter medicinal products, herbal remedies, dietary supplements, complementary and alternative therapies, etc.)
- Relevant medical devices

**4. Details (all available) of Adverse Drug Reaction(s)**

- Full description of reaction(s), including body site and severity
- The criterion (or criteria) for regarding the report as serious
- Description of the reported signs and symptoms
- Specific diagnosis for the reaction
- Onset date (and time) of reaction
- Stop date (and time) or duration of reaction
- Dechallenge and rechallenge information
- Relevant diagnostic test results and laboratory data
- Setting (e.g., hospital, out-patient clinic, home, nursing home)
- Outcome (recovery and any sequelae)
- For a fatal outcome, stated cause of death
- Relevant autopsy or post-mortem findings
- Relatedness of product to reaction(s)/event(s)

**5. Details on Reporter of an ADR**

- Name
- Mailing address
- Electronic mail address
- Telephone and/or facsimile number
- Reporter type (consumer, healthcare professional, etc.)
- Profession (specialty)

**6. Administrative and MAH Details**

- Source of report (spontaneous, epidemiological study, patient survey, literature, etc.)
- Date the event report was first received by manufacturer/company
- Country in which the event occurred
- Type (initial or follow-up) and sequence (first, second, etc.) of case information reported to authorities
- Name and address of MAH
- Name, address, electronic mail address, telephone number, and facsimile number of contact person of MAH
- Identifying regulatory code or number for marketing authorisation dossier
- Company/manufacturer's identification number for the case (the same number should be used for the initial and follow-up reports on the same case).